A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology

T he magnitude of the risk of prostate cancer among Ashkenazi Jewish carriers of the common mutations in the BRCA1 and BRCA2 genes, the so-called Ashkenazi BRCA founder mutations (BRCA1 185delAG and 5382insC, and BRCA2 6174delT), remains uncertain. Two large epidemiological studies have suggested that the cumulative incidence of prostate cancer among male first degree relatives of individuals with a founder mutation may approach 30% by 80 years of age. 1 2 Smaller clinical studies have, in general, not demonstrated an increased frequency of founder mutations among Jewish men with prostate cancer. [3] 4][5][6] Only one study to date has examined clinical characteristics of prostate cancer patients with founder mutations. 3 In this study, the three BRCA associated tumours that were identified appeared to be associated with biologically more aggressive disease, presenting with higher PSA levels, higher Gleason scores and more advanced stage at diagnosis, than did prostate cancers diagnosed in men without mutations.